These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38146568)

  • 41. Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer.
    File DM; Pascual T; Deal AM; Wheless A; Perou CM; Claire Dees E; Carey LA
    Breast Cancer Res Treat; 2022 Nov; 196(1):153-162. PubMed ID: 36008651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study.
    Carlino F; Diana A; Ventriglia A; Piccolo A; Mocerino C; Riccardi F; Bilancia D; Giotta F; Antoniol G; Famiglietti V; Feliciano S; Cangiano R; Lobianco L; Pellegrino B; De Vita F; Ciardiello F; Orditura M
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291765
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
    Ring A; Karuturi M; Smyth EN; Lokhandwala T; Sheffield KM; Willey J; Lunacsek O; Sapunar F; Cui ZL; Coutinho A; Rybowski S
    Adv Ther; 2023 May; 40(5):2515-2523. PubMed ID: 36995468
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype.
    Wu Q; Li J; Zhu S; Wu J; Li X; Liu Q; Wei W; Sun S
    Oncotarget; 2016 Dec; 7(52):87532-87542. PubMed ID: 27655704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence and survival outcomes of early male breast cancer: a population-based comparison with early female breast cancer.
    Wang Y; Chen K; Yang Y; Tan L; Chen L; Zhu L; Su F; Liu X; Li S
    Ann Transl Med; 2019 Oct; 7(20):536. PubMed ID: 31807518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Breast Cancer in Men: a Report from the Department of Radiation Oncology in Kermanshah Province, Iran.
    Amirifard N; Sadeghi E
    Asian Pac J Cancer Prev; 2016; 17(5):2593-6. PubMed ID: 27268636
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group.
    Dogan I; Aksoy S; Cakar B; Basaran G; Ercelep O; Molinas Mandel N; Korkmaz T; Gokmen E; Sener C; Aydiner A; Saip P; Eralp Y
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
    Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
    Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer.
    Ghafouri SR; Guvvala S; Jones C; Philipovskiy A
    J Investig Med; 2022 Aug; 70(6):1329-1341. PubMed ID: 35705261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.
    Vazquez-Martin A; Fernandez-Real JM; Oliveras-Ferraros C; Navarrete JM; Martin-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2009 Dec; 35(6):1369-76. PubMed ID: 19885560
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age.
    Sussell JA; Sheinson D; Wu N; Shah-Manek B; Seetasith A
    Adv Ther; 2020 Apr; 37(4):1632-1645. PubMed ID: 32172510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
    Carausu M; Carton M; Diéras V; Petit T; Guiu S; Gonçalves A; Augereau P; Ferrero JM; Levy C; Ung M; Desmoulins I; Debled M; Bachelot T; Pistilli B; Frenel JS; Mailliez A; Chevrot M; Cabel L
    JAMA Netw Open; 2022 Dec; 5(12):e2247154. PubMed ID: 36520434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical features of patients with male breast cancer in Shanxi province of China from 2007 to 2016.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jia Y; Xi Y; Jing J
    J Investig Med; 2019 Mar; 67(3):699-705. PubMed ID: 30368484
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer.
    Olivera-Salguero R; Seguí E; Cejalvo JM; Oliveira M; Tolosa P; Vidal M; Malumbres M; Gavilá J; Saura C; Pernas S; López R; Margelí M; Balmaña J; Muñoz M; Blancas I; Boni V; Ciruelos E; Galve E; Perelló A; Sánchez-Bayona R; de la Cruz S; de la Hoya M; Galván P; Sanfeliu E; Gonzalez-Farre B; Sirenko V; Blanch-Torras A; Canes J; Masanas H; Olmos R; Forns M; Prat A; Casas A; Pascual T
    Front Oncol; 2023; 13():1151496. PubMed ID: 37188177
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer.
    Kaufman PA; Neuberger E; Schwartz NRM; Wang S; Liu Y; Hsu LI; Bartley K; Blahna MT; Pittner BT; Wong G; Anders C
    Front Oncol; 2023; 13():1264861. PubMed ID: 37849811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer.
    Gilbert A; Williams C; Azuero A; Burkard ME; Kenzik K; Garrett-Mayer E; Meersman S; Rocque G
    Clin Breast Cancer; 2021 Aug; 21(4):292-301. PubMed ID: 33309481
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hormone receptor-positive breast cancer and black race: does sex matter?
    Eskander MF; Li Y; Bhattacharyya O; Tsung A; Oppong BA; Hamad A; Gatti-Mays M; Obeng-Gyasi S
    Breast Cancer Res Treat; 2021 Nov; 190(1):111-119. PubMed ID: 34383180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
    Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
    J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.